Pang Kuin Tian, Tay Shi Jie, Wan Corrine, Walsh Ian, Choo Matthew S F, Yang Yuan Sheng, Choo Andre, Ho Ying Swan, Nguyen-Khuong Terry
Bioprocessing Technology Institute, Agency for Science Technology and Research (ASTAR), Queenstown, Singapore.
Front Chem. 2021 May 18;9:661406. doi: 10.3389/fchem.2021.661406. eCollection 2021.
The glycosylation of antibody-based proteins is vital in translating the right therapeutic outcomes of the patient. Despite this, significant infrastructure is required to analyse biologic glycosylation in various unit operations from biologic development, process development to QA/QC in bio-manufacturing. Simplified mass spectrometers offer ease of operation as well as the portability of method development across various operations. Furthermore, data analysis would need to have a degree of automation to relay information back to the manufacturing line. We set out to investigate the applicability of using a semiautomated data analysis workflow to investigate glycosylation in different biologic development test cases. The workflow involves data acquisition using a BioAccord LC-MS system with a data-analytical tool called GlycopeptideGraphMS along with Progenesis QI to semi-automate glycoproteomic characterisation and quantitation with a LC-MS1 dataset of a glycopeptides and peptides. Data analysis which involved identifying glycopeptides and their quantitative glycosylation was performed in 30 min with minimal user intervention. To demonstrate the effectiveness of the antibody and biologic glycopeptide assignment in various scenarios akin to biologic development activities, we demonstrate the effectiveness in the filtering of IgG1 and IgG2 subclasses from human serum IgG as well as innovator drugs trastuzumab and adalimumab and glycoforms by virtue of their glycosylation pattern. We demonstrate a high correlation between conventional released glycan analysis with fluorescent tagging and glycopeptide assignment derived from GraphMS. GraphMS workflow was then used to monitor the glycoform of our in-house trastuzumab biosimilar produced in fed-batch cultures. The demonstrated utility of GraphMS to semi-automate quantitation and qualitative identification of glycopeptides proves to be an easy data analysis method that can complement emerging multi-attribute monitoring (MAM) analytical toolsets in bioprocess environments.
基于抗体的蛋白质糖基化对于实现患者正确的治疗效果至关重要。尽管如此,从生物制品研发、工艺开发到生物制造中的质量保证/质量控制等各个单元操作中,分析生物糖基化仍需要大量基础设施。简化的质谱仪操作简便,且方法开发可在各种操作中灵活应用。此外,数据分析需要具备一定程度的自动化,以便将信息反馈到生产线。我们着手研究使用半自动化数据分析工作流程来研究不同生物制品研发测试案例中糖基化的适用性。该工作流程包括使用BioAccord液相色谱 - 质谱系统进行数据采集,结合名为GlycopeptideGraphMS的数据分析工具以及Progenesis QI,利用糖肽和肽的液相色谱 - 质谱1数据集对糖蛋白进行半自动化表征和定量。涉及糖肽鉴定及其定量糖基化的数据分析在最少用户干预的情况下30分钟内即可完成。为了证明在类似于生物制品研发活动的各种场景中抗体和生物糖肽分配的有效性,我们通过糖基化模式展示了从人血清IgG中筛选IgG1和IgG2亚类以及创新药物曲妥珠单抗和阿达木单抗及其糖型的有效性。我们证明了传统的荧光标记释放聚糖分析与源自GraphMS的糖肽分配之间具有高度相关性。然后使用GraphMS工作流程监测在补料分批培养中生产的我们内部的曲妥珠单抗生物类似药的糖型。GraphMS对半自动化糖肽定量和定性鉴定的实用价值证明是一种简便的数据分析方法,可以补充生物工艺环境中新兴的多属性监测(MAM)分析工具集。